During the past decade, Kurume University Hospital conducted 89 clinical trials. In the 10-year time frame, 89 clinical trials started and 35 clinical trials were completed, i.e. on average, 39.3% percent of trials that started reached the finish line to date. In the past 5 years, 46 clinical trials started and 31 clinical trials were completed. i.e. 67.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kurume University Hospital" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Janssen Research & Development, LLC" with 12 trials sponsored, "Pfizer" with 10 trials sponsored, "Takeda" with 8 trials sponsored and "Eli Lilly and Company" with 8 trials sponsored. Other sponsors include 49 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kurume University Hospital" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Boehringer Ingelheim" with 2 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator and "GOG Foundation" with 2 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 35 trials.

According to Clinical.Site data, the most researched conditions in "Kurume University Hospital" are "Carcinoma, Non-Small-Cell Lung" (6 trials), "Ovarian Cancer" (6 trials), "Ulcerative Colitis" (5 trials), "Fallopian Tube Cancer" (4 trials) and "Nonalcoholic Steatohepatitis" (4 trials). Many other conditions were trialed in "Kurume University Hospital" in a lesser frequency.

Most popular intervention types in "Kurume University Hospital" are "Drug" (89 trials), "Other" (9 trials), "Device" (5 trials), "Procedure" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Carboplatin" (7 trials), "Paclitaxel" (6 trials), "Atezolizumab" (5 trials) and "Faricimab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Kurume University Hospital" are 87 trials for "All" genders, 13 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Kurume University Hospital". undefined are not yet recruiting, 25 are recruiting, 27 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in Kurume University Hospital, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Kurume University Hospital, 6 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 62 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".